Hypnomidate (Etomidate)

Etomidate acts as a positive allosteric modulator of the GABAA receptor. By binding to specific subunits, it enhances the inhibitory effect of the neurotransmitter GABA, increasing chloride influx and hyperpolarizing neurons. This results in rapid suppression of central nervous system activity, producing sedation and hypnosis while largely preserving cardiovascular stability.

The dosage of Hypnomidate is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Etomidate is typically administered intravenously as a single bolus or as part of an induction protocol, and exact dosing should follow the prescriber’s order and institutional guidelines.

Safety data for etomidate during pregnancy and lactation are limited, and the product is classified with an unknown pregnancy category. Consequently, it should be used only if the potential benefit justifies any possible risk to the fetus or infant, and clinicians should consider alternative agents when safer options are available.

To order Hypnomidate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The most common alternative to etomidate is propofol. While propofol offers rapid induction, it can cause significant hypotension and respiratory depression. Etomidate, by contrast, provides hemodynamic stability with less impact on blood pressure, though it carries a risk of adrenal suppression. Choice of agent depends on the patient’s cardiovascular status and the clinical priorities of the procedure.

Hypnomidate must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, should not be frozen, and must be gently inverted if mixing is required—shaking is avoided to preserve solution integrity.

Hypnomidate is administered intravenously, typically as a rapid bolus injection over 30‑60 seconds for induction of anesthesia. In some protocols, a slower infusion may be used for procedural sedation. Administration should be performed by trained personnel in a setting equipped for airway management and cardiovascular monitoring.

The most serious adverse events include adrenal suppression, which can impair cortisol production; severe allergic reactions ranging from rash to anaphylaxis; respiratory depression that may require ventilatory support; and rare cardiac arrhythmias. Prompt recognition and appropriate supportive measures are essential when these events occur.

Hypnomidate should be avoided in patients with known hypersensitivity to etomidate or any excipients in the formulation. It is also contraindicated in individuals with severe adrenal insufficiency, uncontrolled cardiovascular instability, or those in whom rapid loss of consciousness poses an unacceptable risk without adequate monitoring.